

Correction

Waheed S, Shaughnessy JD, van Rhee F, Alsayed Y, Nair B, Anaissie E, Szymonifka J, Hoering A, Crowley J, Barlogie B. International Staging System and Metaphase Cytogenetic Abnormalities in the Era of Gene Expression Profiling Data in Multiple Myeloma Treated With Total Therapy 2 and 3 Protocols. *Cancer* doi: 10.1002/cncr.25535.

Questions were raised by a reader about the financial disclosures provided by some of the authors of the above paper. The published disclosures were as follows:

“Supported in part by Program project grant CA55819 from the National Cancer Institute, Bethesda, Maryland.”

In response to the concerns raised by the reader, the journal followed up with the authors and asked if there were any additional disclosures that should have been included prior to publication. The authors disclosed the following information:

Dr. Shaughnessy holds patents, or has submitted patent applications, on the use of gene expression profiling in cancer medicine, use of FISH for chromosome 1q21 as a cancer diagnostic, and targeting DKK1 as a cancer and bone anabolic therapy. Dr. Shaughnessy receives royalties related to patent licenses from Genzyme and Novartis. He has advised Celgene, Genzyme, Millennium, and Novartis, and has received speaking honoraria from Celgene, Array BioPharma, Centocor Ortho Biotech, Genzyme, Millennium, and Novartis.

Dr. Barlogie has received research funding from Celgene and Novartis. He is a consultant to Celgene and Genzyme, and has received speaking honoraria from Celgene and Millennium. Dr. Barlogie is a co-inventor on patents and patent applications related to use of gene expression profiling in cancer medicine.

The editors of the journal have reviewed this additional information and determined that although the disclosures are relevant to the publication, they would not have altered the decision to accept the paper. We apologize for the lack of transparency caused by the authors' failure to disclose this information.